医学临床研究
  2025年4月8日 星期二           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2019, Vol. 36 Issue (11): 2131-2133    DOI: 10.3969/j.issn.1671-7171.2019.11.016
  论著 本期目录 | 过刊浏览 | 高级检索 |
左卡尼汀联合呋塞米治疗慢性肾脏病血液透析滤过患者心力衰竭的疗效
蒋佳伟
江苏省宜兴市人民医院肾内科,江苏 宜兴 214200
Effect of L-carnitine Combined with Furosemide on Heart Failure Treatment in Patients with Chronic Kidney Disease undergoing Hemodiafiltration
JIANG Jia-wei
Department of Nephrology, Yixing people's Hospital, Jiangsu Yixing 214200
全文: PDF (0 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 【目的】探讨左卡尼汀联合呋塞米治疗慢性肾脏病(CKD)血液透析滤过(HDF)患者心力衰竭的疗效。【方法】行HDF的CKD合并心力衰竭的患者120例,随机分为两组。对照组予充分HDF和常规抗心衰治疗,观察组在对照组的基础上静脉注射左卡尼汀及呋塞米。两组均连续治疗12周,比较两组疗效,心功能指标,血管紧张素(AngⅡ)、血浆肾素(PRA)、醛固酮(ALD)和N末端脑钠肽前体(NT-proBNP)水平变化,6 min步行距离(6MWT)及不良反应发生率。【结果】治疗后观察组的总有效率为91.67%(55/60),明显高于对照组的75.00%(45/60),且差异有显著性(P<0.05)。治疗后两组AngⅡ、PRA、ALD、NT-proBNP水平和心脏指数、左心室舒张末期内径、舒张末期左心室后壁厚度、室间隔舒张末期厚度较治疗前显著降低(P<0.05),左心室射血分数、6MWT 较治疗前显著升高(P<0.05),且观察组改善水平较对照组更加明显(P<0.05)。两组不良反应发生率比较差异无显著性(P>0.05)。【结论】应用左卡尼汀联合呋塞米治疗CKD行HDF患者心力衰竭疗效显著,能明显改善心功能,增加6MWT ,且安全性良好,值得临床推广应用。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
蒋佳伟
关键词 肾疾病慢性病血液透析滤过肉碱/药理学呋塞米/药理学    
Abstract【Objective】To investigate the efficacy of L-carnitine combined with furosemide in the treatment of heart failure patients with chronic kidney disease(CKD)undergoing hemodiafiltration (HDF). 【Methods】A total of 120 CKD patients with HDF, who complicated with heart failure, were randomly divided into two groups. The control group received proper HDF and conventional anti-heart failure treatment. While the observation group received intravenous injection of L-carnitine and furosemide on the basis of treatment in the control group. Patients in the two groups were treated continuously for 12 weeks . Cardiac function indicators, angiotensin (Ang Ⅱ), plasma renin (PRA), aldosterone (ALD) and N-terminal pro-brain natriuretic peptide (NT-proBNP), 6 min walking distance(6MWT) and incidence of adverse reactions were compared between two groups. 【Results】After treatment, the total effective rate of the observation group was 91.67% (55/60), which was significantly higher than that of the control group 75.00% (45/60); the difference was statistically significant (P<0.05). In both groups, the levels of AngⅡ, PRA, ALD, NT-proBNP, cardiac index (CI), LVEDD, LVPWT and IVST after treatment were significantly lower than those before treatment; While the levels of LVEF and 6MWT were significantly higher than those before treatment (P<0.05). The improvement level of the observation group was more obvious than that of the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). 【Conclusion】The application of L-carnitine combined with furosemide in the treatment of heart failure patients with CKD undergoing HDF has good efficacy, which shows significant improvement of patients' cardiac function and 6MWT. It is safe and worthy of clinical application.
Key wordsKidney Diseases    Chronic Disease    Hemodiafiltration    Carnitine/PD    Furosemide/PD
收稿日期: 2018-09-06     
PACS:  R692  
引用本文:   
蒋佳伟. 左卡尼汀联合呋塞米治疗慢性肾脏病血液透析滤过患者心力衰竭的疗效[J]. 医学临床研究, 2019, 36(11): 2131-2133.
JIANG Jia-wei. Effect of L-carnitine Combined with Furosemide on Heart Failure Treatment in Patients with Chronic Kidney Disease undergoing Hemodiafiltration. JOURNAL OF CLINICAL RESEARCH, 2019, 36(11): 2131-2133.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2019.11.016     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2019/V36/I11/2131
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn